[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353431-105":59,"doc-detail-353431-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ex-vivo-tumor-derived-organoid-pharmacotyping-identifies-personalized-therapeutic-options-for-patients-with-biliary-tract-cancer","Ex Vivo Tumor-Derived Organoid Pharmacotyping - Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer","","Biliary tract cancers (BTC) present major clinical challenges due to poor chemotherapy response and an aggressive disease course. A multicenter study assessed patient-derived tumor organoid drug sensitivity testing to guide therapy: 26 organoids were derived from 43 patients and screened against ~50 cancer-directed therapies using the PARIS assay. Although most organoids came from late-stage disease, 92.3% showed strong sensitivity to one or more targeted agents, including several pathway inhibitors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ex-vivo-tumor-derived-organoid-pharmacotyping-identifies-personalized-therapeutic-options-for-patients-with-biliary-tract-cancer/353431/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ex-vivo-tumor-derived-organoid-pharmacotyping-identifies-personalized-therapeutic-options-for-patients-with-biliary-tract-cancer/353431.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were tumor organoids and drug sensitivity testing performed in this study?","Question",{"text":112,"@type":113},"Patient-derived tumor organoids were derived from BTC patients and tested using the Clinical Laboratory Improvement Amendments–certified PARIS assay against an average of about 50 cancer-directed therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What proportion of organoids showed strong sensitivity to targeted agents?",{"text":117,"@type":113},"Despite most organoids originating from late-stage disease, 24 of 26 organoids (92.3%) exhibited strong sensitivity to one or more targeted agents.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the results guide therapy for patients with biliary tract cancer?",{"text":121,"@type":113},"In five cases, the organoid pharmacotyping results guided treatment, including a patient with an FGFRBICC1 fusion who was refractory to FGFR inhibitors and responded to dasatinib with symptomatic improvement, stable disease, and over eight months of survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353431,1790298537,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-25-0792](https://doi.org/10.1158/2767-9764.CRC-25-0792)  OPEN ACCESS  \nEx Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer  \nAnnie Blair Richardson1, Payel Chatterjee1, Rachele Rosati1, Alex Rajewski2, Robert L. Diaz1,  \nLauren R. Appleyard1, Shalini Pereira1, Brady Bernard1,3, Milind M. Javle4, Gentry G. King5, Adam Diehl5, William Proctor Harris5, Sameek Roychowdhury6, Christopher J. Kemp7, and Carla Grandori1  \n􀀶  \nABSTRACT  \nBiliary tract cancers (BTC) pose clinical challenges due to poor chemotherapy response and aggressive disease course. We evaluated patient-derived tumor organoid–based drug sensitivity testing as a tool to guide therapy. In this multicenter study, 26 tumor organoids were successfully derived from 43 patients with BTC and tested with an average of 50 cancer-directed therapies using the Clinical Laboratory Improvement Amendments–certified PARIS assay. Despite most organoids being from late-stage disease, 24/26 (92.3%) exhibited strong sensitivity to one or more targeted agents. Active drugs included inhibitors of EGFR/HER2, MEK, ERK, BCR-ABL and SRC family, mTOR, PI3K, MDM2, BCL2, and BET. Drug sensitivities aligned with  \nknown genetic biomarkers but were also observed in cultures lacking them, indicating ex vivo testing can expand actionability beyond genomics. In five cases, results guided therapy; one patient with an FGFRBICC1 fusion refractory to FGFR inhibitors responded to dasatinib, achieving symptomatic improvement, stable disease, and >8-month survival.  \nSignificance: Ex vivo drug testing of tumor-derived organoids is clinically feasible and can be used to identify personalized treatment options for patients with BTC, to evaluate the functional relevance of genomic biomarkers, and to guide treatment in real time.  \nIntroduction  \nBiliary tract cancer (BTC) is the second most common primary liver cancer, with an estimated 12,000 new cases per year in the United States ( 1, 2) . BTCs are heterogeneous epithelial neoplasms and are subdivided into gallbladder cancer, intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma (eCCA), and combined hepatocellular cholangiocarcinoma (HCC-CCA), each of which has distinct genetic profiles, biology, and clinical features (3, 4) . Approximately 60% to 70% of patients present with  \n1Cure First, Bothell, Washington. 2Tempus AI, Chicago, Illinois. 3Providence Cancer Institute, Portland, Oregon. 4The University of Texas MD Anderson Cancer Center, Houston, Texas. 5Department of Gastrointestinal Medical Oncology, University of Washington School of Medicine, Seattle, Washington. 6Ohio State University Comprehensive Cancer Care Center, Columbus, Ohio. 7Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington.  \nA. B. Richardson and P. Chatterjee contributed equally to this article.  \nCorresponding Author: Payel Chatterjee, Cure First, 22125 17th Ave SE Suite 117,  \nBothell, [WA 98021. E-mail:](WA 98021. E-mail: payel.chatterjee@cure-first.org)[ payel.chatterjee@cure-first.org](WA 98021. E-mail: payel.chatterjee@cure-first.org)  \n[doi:](doi: 10.1158/2767-9764)[ 10.1158/2767-9764](doi: 10.1158/2767-9764) .CRC-25-0792  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.  \n©2026 The Authors; Published by the American Association for Cancer Research  \ninoperable or metastatic disease, and there is a high relapse rate in patients who undergo surgery (5) .  \nThe preferred first-line therapy for advanced BTC in patients eligible for intensive systemic therapy includes combinations of cisplatin, gemcitabine, and either durvalumab or pembrolizumab (National Comprehensive Cancer Network guidelines). Second-line systemic therapy for patients lacking targetable genomic alterations includes folinic acid, fluorouracil and oxaliplatin (FOLFOX; ABC-06","cbCailMxZqtK3LJk","https://ap.wps.com/l/cbCailMxZqtK3LJk","pdf",6520101,13,"English","# Abstract\n## Significance\n# Introduction","[{\"question\":\"How were tumor organoids and drug sensitivity testing performed in this study?\",\"answer\":\"Patient-derived tumor organoids were derived from BTC patients and tested using the Clinical Laboratory Improvement Amendments–certified PARIS assay against an average of about 50 cancer-directed therapies.\"},{\"question\":\"What proportion of organoids showed strong sensitivity to targeted agents?\",\"answer\":\"Despite most organoids originating from late-stage disease, 24 of 26 organoids (92.3%) exhibited strong sensitivity to one or more targeted agents.\"},{\"question\":\"How did the results guide therapy for patients with biliary tract cancer?\",\"answer\":\"In five cases, the organoid pharmacotyping results guided treatment, including a patient with an FGFRBICC1 fusion who was refractory to FGFR inhibitors and responded to dasatinib with symptomatic improvement, stable disease, and over eight months of survival.\"}]","Ex Vivo Tumor-Derived Organoid Pharmacotyping - Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer | PDF",1790105359,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a53886ddcc308272bc533465792c3824.webp",983,1263,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1b5f92100f0af7fb473fa82d0800863.webp",982,1262,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01b06a76684fd8aaf9f265580a3171ae.webp",981,1261,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e35d33db544b43158861834db446c8fa.webp",980,1259]